Strategies to achieve low-density lipoprotein cholesterol targets in high-risk patients

被引:0
作者
Mantsiou, Chrysanthi [1 ]
Tziomalos, Konstantinos [1 ]
机构
[1] Aristotle Univ Thessaloniki, AHEPA Hosp, Med Sch, Propedeut Dept Internal Med 1, Thessaloniki, Greece
关键词
Atorvastatin; rosuvastatin; ezetimibe; PCSK9; inhibitors; low-density lipoprotein cholesterol targets; INTENSITY STATIN THERAPY; PCSK9; INHIBITORS; ATORVASTATIN; CORONARY; METAANALYSIS; PREVENTION; GUIDELINES; EZETIMIBE; DISEASE; STROKE;
D O I
10.1080/03007995.2018.1510224
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several options exist in very-high risk patients who do not achieve low-density lipoprotein cholesterol (LDL-C) targets despite treatment with atorvastatin 80 mg, including switching to rosuvastatin 40 mg, adding ezetimibe or adding a proprotein convertase subtilisin/kexin type 9 inhibitor. Taking into account the safety, LDL-C lowering capacity, effect on cardiovascular events and cost of these available options, switching to rosuvastatin 40 mg appears to represent the most attractive strategy. Nevertheless, more studies are needed to confirm the effects of this strategy on LDL-C levels given the limited available data.
引用
收藏
页码:1713 / 1715
页数:3
相关论文
共 23 条
  • [1] Amarenco P, 2006, NEW ENGL J MED, V355, P549
  • [2] Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers Insights Derived From the FOURIER Trial
    Arrieta, Alejandro
    Hong, Jonathan C.
    Khera, Rohan
    Virani, Salim S.
    Krumholz, Harlan M.
    Nasir, Khurram
    [J]. JAMA CARDIOLOGY, 2017, 2 (12) : 1369 - 1374
  • [3] Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
    Cannon, Christopher P.
    Blazing, Michael A.
    Giugliano, Robert P.
    McCagg, Amy
    White, Jennifer A.
    Theroux, Pierre
    Darius, Harald
    Lewis, Basil S.
    Ophuis, Ton Oude
    Jukema, J. Wouter
    De Ferrari, Gaetano M.
    Ruzyllo, Witold
    De Lucca, Paul
    Im, KyungAh
    Bohula, Erin A.
    Reist, Craig
    Wiviott, Stephen D.
    Tershakovec, Andrew M.
    Musliner, Thomas A.
    Braunwald, Eugene
    Califf, Robert M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) : 2387 - 2397
  • [4] 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
    Catapano, Alberico L.
    Graham, Ian
    De Backer, Guy
    Wiklund, Olov
    Chapman, M. John
    Drexel, Heinz
    Hoes, Arno W.
    Jennings, Catriona S.
    Landmesser, Ulf
    Pedersen, Terje R.
    Reiner, Zeljko
    Riccardi, Gabriele
    Taskinen, Marja-Riita
    Tokgozoglu, Lale
    Verschuren, W. M. Monique
    Vlachopoulos, Charalambos
    Wood, David A.
    Luis Zamorano, Jose
    [J]. ATHEROSCLEROSIS, 2016, 253 : 281 - 344
  • [5] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Colhoun, HM
    Betteridge, DJ
    Durrington, PN
    Hitman, GA
    Neil, HAW
    Livingstone, SJ
    Thomason, MJ
    Mackness, MI
    Charlton-Menys, V
    Fuller, JH
    [J]. LANCET, 2004, 364 (9435) : 685 - 696
  • [6] To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis
    Karlson, Bjorn W.
    Palmer, Michael K.
    Nicholls, Stephen J.
    Lundman, Pia
    Barter, Philip J.
    [J]. ATHEROSCLEROSIS, 2015, 241 (02) : 450 - 454
  • [7] 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
    Landmesser, Ulf
    Chapman, M. John
    Stock, Jane K.
    Amarenco, Pierre
    Belch, Jill J. F.
    Boren, Jan
    Farnier, Michel
    Ference, Brian A.
    Gielen, Stephan
    Graham, Ian
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 (14) : 1131 - 1143
  • [8] Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    LaRosa, JC
    Grundy, SM
    Waters, DD
    Shear, C
    Barter, P
    Fruchart, J
    Gotto, AM
    Greten, H
    Kastelein, JJP
    Shepherd, J
    Wenger, NK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (14) : 1425 - 1435
  • [9] Lewington S, 2007, LANCET, V370, P1829, DOI 10.1016/S0140-6736(07)61778-4
  • [10] LDL cholesterol levels after switch from atorvastatin to rosuvastatin
    Lewis, Sandra J.
    Olufade, Temitope
    Anzalone, Deborah A.
    Malangone-Monaco, Elisabetta
    Evans, Kristin A.
    Johnston, Stephen
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (10) : 1717 - 1723